Enumeral Biomedical Holdings, Inc. and Merck, through a subsidiary, have signed an oncology collaboration study agreement to use Enumeral’s human approach in colorectal cancer tissues from patients to identify cellular responses to immune-oncology therapies being developed by Merck.   Enumeral’s immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Enumeral will receive R&amp...